Concluding Remarks
New insights into the pathophysiology of the motor and sensory components of the functional gastrointestinal disorders augur well for major advances and novel therapies. The spiraling costs associated with healthcare utilization, as well as the economic burden incurred indirectly from these conditions, require a concerted effort on the part of clinicians to respond to the challenges of diagnosing and managing these disorders of function.
Michael Camilleri, MD, has disclosed that he receives research grant funding from Glaxo Wellcome, Novartis, SmithKline Beecham, Janssen Pharmaceuticals, TAP Pharmaceuticals, Abbott Laboratories, and Merck. He holds consulting agreements with Janssen Pharmaceuticals, Novartis, SmithKline Beecham, and Glaxo Wellcome.
Medscape General Medicine. 1999;1(3) © 1999
Cite this: Functional Gastrointestinal Disorders: Novel Insights and Treatments - Medscape - Nov 01, 1999.
